Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Case Reports in Oncology 2015;8:189–195. DOI: 10.1159/000381983
- Keyword
-
Krebs
Onkologie
- Event
-
Veröffentlichung
- (where)
-
Würzburg
- (who)
-
Universität Würzburg
- (when)
-
2016
- Creator
- URN
-
urn:nbn:de:bvb:20-opus-126093
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Danhof, Sophia
- Schreder, Martin
- Strifler, Susanne
- Einsele, Hermann
- Knop, Stefan
- Universität Würzburg
Time of origin
- 2016
Other Objects (12)
Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis
Herausforderungen in der Onkologie - personalisierte Therapiesteuerung : virtuelle DGHO Frühjahrstagung 2023 : 22. Maärz 2023, 29. März 2023, 26. April 2023
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network
Keimarm kochen : Rezepte und Empfehlungen für Menschen mit Immunsuppression
Development and preclinical assessment of ROR2-specific CAR-T cells for the treatment of clear cell renal cell carcinoma and multiple myeloma
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study
Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines
Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis
Herausforderungen in der Onkologie - personalisierte Therapiesteuerung : virtuelle DGHO Frühjahrstagung 2023 : 22. Maärz 2023, 29. März 2023, 26. April 2023
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network
Keimarm kochen : Rezepte und Empfehlungen für Menschen mit Immunsuppression
Development and preclinical assessment of ROR2-specific CAR-T cells for the treatment of clear cell renal cell carcinoma and multiple myeloma
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study
Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines
Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis
Herausforderungen in der Onkologie - personalisierte Therapiesteuerung : virtuelle DGHO Frühjahrstagung 2023 : 22. Maärz 2023, 29. März 2023, 26. April 2023
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network
Keimarm kochen : Rezepte und Empfehlungen für Menschen mit Immunsuppression
Development and preclinical assessment of ROR2-specific CAR-T cells for the treatment of clear cell renal cell carcinoma and multiple myeloma
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers
Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study